(RTTNews) - Beam Therapeutics Inc. (BEAM) Monday reported positive initial data from its Phase 1/2 study of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD).
AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease
BEAM-302 is being evaluated in a Phase 1/2 study to evaluate its safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy. Part A of the trial is designed to evaluate AATD patients with lung disease, and Part B will evaluate AATD patients with mild to moderate liver disease with or without lung disease.
Preliminary results from the first three single-ascending dose cohorts showed that BEAM-302 was well tolerated, with single doses of BEAM-302 leading to durable dose-dependent correction of the disease-causing mutation. Further, no serious adverse events were reported.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
